AffaMed Signs $145 Million Agreement for China Rights to Ophthalmic Drug

Shanghai AffaMed acquired greater China rights to an ophthalmic drug from Korea 's Hanmi Pharma in an $145 million agreement. AffaMed will have rights to manufacture, develop and commercialize risuteganib (Luminate®), a first-in-class intravitreal injectable product that targets intermediate Dry Age-related Macular Degeneration and other vitreo-retinal diseases. Hanmi will receive $6 million upfront plus milestones and royalties. In 2020, CBC Group merged two of its portfolio companies, AffaMed and EverInsight Therapeutics, into a single entity under the AffaMed name. More details.... Share this with colleagues: // //